非管腔亚型肌层浸润性膀胱癌从铂类新辅助化疗中获益最大
该研究纳入4个膀胱癌队列共601例肌层浸润性膀胱癌患者,其中247例接受新辅助化疗加根治性膀胱切除术,354例仅行根治性膀胱切除术;采用商业基因组亚型分类器确定分子亚型,并用逆概率加权使基线特征可比。结果显示新辅助化疗对总生存和癌症特异性生存的3年绝对净获益分别为7%和5%;控制临床病理变量后,非管腔亚型肿瘤从新辅助化疗中获益最大,3年总生存提高10%(71% vs 61%),而管腔亚型肿瘤获益甚微(63% vs 65%)。
要点
- 非管腔亚型肌层浸润性膀胱癌接受新辅助化疗3年总生存绝对获益10%(71% vs 61%)。
- 管腔亚型肿瘤从新辅助化疗中获益甚微(63% vs 65%)。
- 商业基因组亚型分类器可能有助于筛选最受益于新辅助化疗的患者。
核心结论
- 在肌层浸润性膀胱癌患者中,商业可及的分子亚型检测显示非管腔肿瘤从新辅助化疗中获益最大,而管腔肿瘤的生存获益甚微。
- 基因组分类器可能有助于识别最可能从新辅助化疗中获益的肌层浸润性膀胱癌患者。
研究设计与样本
- 研究纳入4个膀胱癌队列,共601例肌层浸润性膀胱癌患者。
- 247例接受新辅助化疗加根治性膀胱切除术,354例仅行根治性膀胱切除术。
- 采用逆概率加权使新辅助化疗组与未化疗组的年龄、性别和临床肿瘤分期等基线特征更可比。
- 分子亚型通过商业基因组亚型分类器确定。
- 生存率用加权Kaplan-Meier曲线估计,Cox比例风险模型评估总生存和癌症特异性生存终点。
主要发现
- 新辅助化疗对总生存和癌症特异性生存的3年总体净获益分别为7%和5%。
- 控制临床病理变量后,非管腔肿瘤从新辅助化疗中获益最大,3年总生存提高10%(71% vs 61%)。
- 管腔肿瘤从新辅助化疗中获益甚微,3年总生存为63% vs 65%。
临床怎么用
- 对于肌层浸润性膀胱癌患者,可考虑采用商业基因组亚型分类器辅助筛选最可能从铂类新辅助化疗中获益的人群。
- 非管腔亚型患者可能从新辅助化疗中获得更大的总生存绝对获益,而管腔亚型患者获益有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) in patients with nonmetastatic muscle-invasive bladder cancer (MIBC) confers an absolute survival benefit of 5%-10%. There is evidence that molecular differences between tumors may impact response to therapy, highlighting a need for clinically validated biomarkers to predict response to NAC. MATERIALS AND METHODS: Four bladder cancer cohorts were included. Inverse probability weighting was used to make baseline characteristics (age, sex and clinical tumor stage) between NAC-treated and untreated groups more comparable. Molecular subtypes were determined using a commercial genomic subtyping classifier. Survival rates were estimated using weighted Kaplan-Meier curves. Cox proportional hazards models were used to evaluate the primary and secondary study end points of overall survival (OS) and cancer-specific survival, respectively. RESULTS: A total of 601 patients with MIBC were included, of whom 247 had been treated with NAC and RC, and 354 underwent RC without NAC. With NAC, the overall net benefit to OS and cancer-specific survival at 3 years was 7% and 5%, respectively. After controlling for clinicopathological variables, nonluminal tumors had greatest benefit from NAC, with 10% greater OS at 3 years (71% vs 61%), while luminal tumors had minimal benefit (63% vs 65%) for NAC vs non-NAC. CONCLUSIONS: In patients with MIBC, a commercially available molecular subtyping assay revealed nonluminal tumors received the greatest benefit from NAC, while patients with luminal tumors experienced a minimal survival benefit. A genomic classifier may help identify patients with MIBC who would benefit most from NAC.
引用
- Lotan Y, de Jong JJ, Liu VYT, et al. Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy. J Urol. 2021. PMID: 34643090. doi:10.1097/JU.0000000000002261
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。